News | Genetic Testing | November 09, 2016

Sudden Cardiac Death of Teen Illustrates Necessity of Proper Genetic Testing

Mayo Clinic research reveals that 20 relatives were incorrectly diagnosed with potentially lethal heart rhythm condition following 13-year-old’s death

genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings

November 9, 2016 — The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having a potentially lethal heart rhythm condition. This erroneous diagnosis occurred as a result of inappropriate use of genetic testing and incorrect interpretation of genetic test results, according to Mayo Clinic research published in Mayo Clinic Proceedings.

This case highlights the potential danger of genetic testing when it is used incorrectly, and the great need to not only use this powerful tool carefully and wisely but to scrutinize the results with great caution, said senior author Michael J. Ackerman, M.D., Ph.D., genetic cardiologist and director of Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Laboratory.

“While the technological advances in genetic sequencing have been exponential, our ability to interpret the results has not kept pace,” he said.

Following the boy’s death, family members were diagnosed with long QT syndrome, an inherited heart rhythm condition that potentially can cause fast and chaotic heartbeats. In some cases, it can cause sudden cardiac death. People can be born with a genetic mutation that puts them at risk of long QT syndrome. As a result, the boy’s brother prophylactically received an implantable cardioverter defibrillator, which can stop a potentially fatal arrhythmia. Specific genetic testing was performed throughout the father’s side of the family, leading to the eventual, but incorrect, diagnosis of long QT syndrome in more than 20 family members, Ackerman said.

The family then traveled to Mayo Clinic for a second opinion. During the course of their initial clinical evaluations, Ackerman became skeptical quickly of their previous diagnosis. Over the years, 40 percent of the patients who came to Mayo Clinic with the diagnosis of long QT syndrome left without the diagnosis, with the vast majority reclassified as normal.

“This family’s case appeared to be another case of mistaken identity with wrong conclusions being rendered to the data ascertained, especially the genetic test results,” he said. “In fact, none of the relatives who sought a second opinion at Mayo Clinic had personal symptoms of long QT syndrome, and none exhibited any electrocardiographic evidence of long QT syndrome at rest or with treadmill stress testing.” Since receiving the implantable cardioverter-defibrillator, the boy’s brother has had two inappropriate shocks delivered.

Then, with this clinical doubt raised, Ackerman and co-investigators worked to discover the true reason behind the boy’s death. The research team used the molecular autopsy that was pioneered by Ackerman and his team. First performed in the late 1990s, the molecular autopsy has advanced to what Ackerman refers to as “the whole-exome molecular autopsy coupled with genomic triangulation.” This strategy “provided closure and clarity” for the family, he said. “We discovered that the boy died tragically from an abnormal heart muscle condition caused by an entirely different genetic defect — unrelated to long QT syndrome — that was confined to only the sudden death victim,” Ackerman said.

“This family study highlights just how important it is to get things right on the first attempt, as it takes a tremendous amount of time, energy and money to reverse course and do it over again. It also depicts exactly the wrong way of using genetic testing and also precisely the right way of using and interpreting genetic testing. Ultimately, the clinician’s long-standing role to meticulously phenotype (characterize) his or her patient and his or her family is what matters most. When the pursuit of the genotype gets in front of the establishment of the phenotype, bad things happen,” Ackerman said.

Co-authors are: Jaeger Ackerman, Jamie Kapplinger, David Tester, all of Mayo Clinic; Daniel Bartos, Ph.D., University of Kentucky and University of California, Davis; and Brian Delisle, Ph.D., University of Kentucky.

For more information: www.mayoclinicproceedings.org

Related Content

Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Overlay Init